JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 163 filers reported holding JUNO THERAPEUTICS INC in Q4 2015. The put-call ratio across all filers is 2.35 and the average weighting 1.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2017 | $1,226,000 | +318.4% | 26,830 | +310.7% | 0.01% | +300.0% |
Q3 2017 | $293,000 | +17.7% | 6,533 | +0.9% | 0.00% | 0.0% |
Q2 2016 | $249,000 | +16.9% | 6,475 | +15.9% | 0.00% | +100.0% |
Q1 2016 | $213,000 | +15.1% | 5,589 | +32.7% | 0.00% | 0.0% |
Q4 2015 | $185,000 | – | 4,212 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Crestline Management, LP | 25,948,799 | $1,132,937,000 | 100.00% |
Biomark Capital Management Co. LLC | 1,602,562 | $70,465,000 | 85.76% |
Omega Fund Management, LLC | 1,229,512 | $54,062,000 | 30.09% |
Clarius Group, LLC | 218,942 | $9,626,000 | 2.93% |
BB BIOTECH AG | 1,305,000 | $57,381,000 | 1.62% |
Casdin Capital, LLC | 17,500 | $769,000 | 0.68% |
Rock Springs Capital Management LP | 197,001 | $8,662,000 | 0.66% |
BENNETT LAWRENCE MANAGEMENT L L C/NY | 38,850 | $1,708,000 | 0.55% |
ArrowMark Colorado Holdings LLC | 383,749 | $16,873,000 | 0.46% |
SUFFOLK CAPITAL MANAGEMENT LLC | 68,848 | $3,027,000 | 0.38% |